Dr. Esteban Pombo-Villar, the Chief Executive Officer of TargImmune Therapeutics, has over 30 years of experience in leading biopharmaceutical R&D and business development. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management, and as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), Prior to that as medicinal chemist…

Dr. Maya Zigler has played a major role in the establishment of TargImmune and its activities. Dr Zigler completed her Ph.D at M.D. Anderson Cancer Center, Houston, Texas on melanoma metastases and progression. She has significant expertise and specialized knowledge in cancer biology. Dr. Zigler joined Professor Alex Levitzki’s laboratory as a postdoc in 2011 where she conducted extensive research, focused on expanding and improving the CTPIC technology to target additional cancer targets. She secured the ERC POC grant in 2013 for the Levitzki laboratory to pursue the CTPIC technology…

Dr. Alex Fässler has over 20 years of experience in operations management in the biopharmaceutical industry. He was previously Chief Operations Officer and member of the Corporate Executive Committee of Bachem, a leading service provider and CMO for peptides. Since 1998 he has held various management positions within the Bachem group, namely as Head of Production, Site Manager and finally COO of the US Organization. Alex Fässler started his industrial career as Medicinal Chemist at Ciba-Geigy, later Novartis, where he was engaged in drug discovery…

Dr. Frank Hennecke, the Head of CMC at TargImmune Therapeutics, has over 20 years experience in biopharmaceutical drug development, production, and clinical supply, and has held executive management positions in both publicly traded and privately held biotech companies. Dr. Hennecke has been working with pioneering immuno-oncology companies, among them Boston based Checkmate Pharmaceuticals and Munich based Rigontec, where he was the responsible lead for CMC in the acquisition process of Rigontec by MSD for up to €464 million. Prior to that he worked with Zurich based Cytos Biotechnology…

Dr. Eric Kitas is the Head of Chemistry at TargImmune Therapeutics AG.  A Medicinal Chemist, he was previously Senior Principal Scientist, Team Leader in the pRED Division of F. Hoffmann-La Roche AG, Basel. He has over 20 years’ experience in cutting edge drug discovery and project leadership across multiple disease areas including Neuroscience, Cardiovascular & Metabolism, Ophthalmology and Oncology. An Australian citizen, he completed both undergraduate and graduate degrees at The University of Melbourne. At the end of 1990 he joined Roche…

Christoph Rentsch is an expert in private and public funding markets and an executive corporate finance leader with more than 25 years of experience in the life science field. He started his career in investment banking and worked in senior management functions for the Alusuisse-Lonza Group both in Switzerland and in the USA. In 1994 he returned to Switzerland to join Roche as Head Group Funding and Capital Markets, taking responsibility for worldwide finance transactions. In 2004 he became managing partner of Caperis Ltd, a life science investment management firm…

Kaspar Kunz, the external Head of Finance of Targimmune Therapeutics, has over 20 years of experience in accounting, auditing and other CFO-services. He is a founding partner of Hoffmann & Partner, a professional services company specializing in corporate finance and CFO-services. As part of the services, he provides with his company CFO-services and acts as part-time CFO for various life science companies in Switzerland. Before co-founding Hoffmann & Partner, Kaspar Kunz spent over ten years at Deloitte in Switzerland, Australia and New Zealand…

Catherine is an experienced executive and advisor who held various managerial roles (with focus in HR Management, organizational development, Compensation & Benefits and international contract law) in various international companies on local, regional and global level (Panalpina, Straumann). In 2013, Catherine decided to run her own HR Advisory company which is specialized in supporting Biotech companies in all HR related matters. From 2015 to 2019 she acted as Global Head Human Resources at Santhera Pharmaceuticals…

Kuno Sommer, Ph.D., today focuses on active board memberships in the life sciences sector as non-executive member. He became Chairman of the Board of the Bachem Group starting in 2012. In his last operational role he headed the contract research division of Harlan Laboratories Ltd. From 2000 until 2006 he was CEO of Berna Biotech Ltd, which was sold to Crucell N.V. in 2006 (today Johnson & Johnson). Starting in 1986 at F. Hoffmann-La Roche Ltd he worked in various functions until 1999 and spent 4 years in the US. In his last position at Roche he became a member of the Executive Committee…

Dr. Peter Kash is a co-founder and a lead investor in TargImmune Therapeutics. He is a global biotech entrepreneur and has raised significant capital for private biotech companies. He has co-founded and co-financed more than a dozen biotech companies. Collectively the companies he co-founded have 6 FDA approved drugs. Dr. Kash was a Adjunct Professor of Entrepreneurship at the Wharton School of Business and has been a Visiting Professor at several other leading universities including Hebrew University in Israel and Nihon University in Japan…

Professor of biochemistry at the Hebrew University of Jerusalem.  Early in his career he earned his Ph.D. in (Biochemistry and Biophysics) Summa cum Laude at The Hebrew University in Jerusalem and The Weizmann Institute. Amongst many visiting professorships he also served as a Fogarty International Scholar at the National Institutes of Health, Bethesda, Maryland. Several of his outstanding honors include: The Israel Prize in Biochemistry (1990), the Rothschild Prize in Biology (1990), The Wolf Prize in Medicine (2005), The EMET Prize for Cancer Research (2017)…

Christoph Rentsch is an expert in private and public funding markets and an executive corporate finance leader with more than 25 years of experience in the life science field. He started his career in investment banking and worked in senior management functions for the Alusuisse-Lonza Group both in Switzerland and in the USA. In 1994 he returned to Switzerland to join Roche as Head Group Funding and Capital Markets, taking responsibility for worldwide finance transactions. In 2004 he became managing partner of Caperis Ltd, a life science investment management firm…

Professor of biochemistry at the Hebrew University of Jerusalem.  Early in his career he earned his Ph.D. in (Biochemistry and Biophysics) Summa cum Laude at The Hebrew University in Jerusalem and The Weizmann Institute. Amongst many visiting professorships he also served as a Fogarty International Scholar at the National Institutes of Health, Bethesda, Maryland. Several of his outstanding honors include: The Israel Prize in Biochemistry (1990), the Rothschild Prize in Biology (1990), The Wolf Prize in Medicine (2005), The EMET Prize for Cancer Research (2017)…

Winzer Professor of Medicine in the Department of Structural Biology at Stanford University, Stanford, California. In 2006 he was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of eukaryotic transcription, the process by which DNA is copied to RNA.  In 2009, he was elected a Foreign Member of the Royal Society. During his career, he received numerus awards including the Eli Lilly Award, the Passano Award, the Ciba-Drew Award, the Gairdner International Award (shared with R. Roeder), the Pasarow Award in Cancer Research, the Le Grand Prix Charles-Leopold Mayer…

Full Professor of Translational Oncology at the Departments of Medical Oncology and Biomedicine, Cancer Immunology at the University Hospital Basel, Switzerland. In these functions he is Co-Chair of the Department of Oncology with a clinical focus on melanoma and lung cancer, conducting clinical trials as well as supervising clinical research in his laboratory focusing on translational research in the area of cancer immunotherapy and the development of novel targeted cancer therapies. Prof. Zippelius studied medicine at Ludwig-Maximilians-University (LMU) Munich, Germany…

Former Chairman of the Division of Oncology at The Chaim Sheba Medical Center, Tel Hashomer, Israel and Clinical Professor of Oncology (Emeritus) at the Tel-Aviv University. Prof. Catane served as the Director of the Institute of Oncology at Shaare Tzedek Medical Center in Jerusalem, Director of Clinical Cancer Research-Pharmaceutical Research Institute at Bristol-Myers Squibb in Connecticut, USA, and Acting Head of the Sharett Institute of Oncology at Hadassah University Hospital in Jerusalem. He has held positions as Guest Researcher, Clinical Associate and Special Assistant…